pfs1 semaglutide – the Surprising New Anti-Fibrosis Drug Semaglutide GLP-1 for Weight Loss
Description
Conference Reports for NATAP The International Liver Congress EASL - European Association for the Study of the Liver June 21-24 2023 Back Pemvidutide Cuts NAFLD Liver Fat and Weight Through 24 Weeks EASL Congress 2023, June 21-24, Vienna Mark Mascolini Pemvidutide, a novel multiactive agent being developed for obesity and nonalcoholic steatohepatitis (NASH), promoted quick and large drops in liver fat content (LFC), weight, and liver enzymes after 12 and 24 weeks in a 94-person placebo-controlled trial [1]
Fuss IJ, Neurath M, Boirivant M, Klein JS, de la Motte C, Strong SA, et al
Doctors consider this information when prescribing semaglutide to their patients
Originally developed for type 2 diabetes management, Semaglutide showed significant weight loss benefits in clinical settings
This knowledge allows you to take proactive steps to manage your side effects and improve your comfort while taking the medication
